| Browse All

Immuneering Corporation (IMRX)

Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
5.53 USD -0.03 (-0.540%) ⇩ (April 20, 2026, 4 p.m. EDT)

Short-term: ★★★☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 19, 2026, 1:45 a.m. EDT

Despite analyst upgrades and significant positive trial data supporting 43% upside, the immediate market narrative is defensive. The company is booking put-heavy flow after news of the pancreatic drug's survival data, creating a short-term headwind. While the risk-reward profile looks attractive long-term given the cash-rich balance sheet and high valuation caps, the fundamental pressure from the recent data readout suggests a higher probability of a near-term pullback or consolidation prior to any upside move.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.049076
AutoETS0.049365
AutoARIMA0.049371
MSTL0.057182

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 80%
H-stat 0.46
Ljung-Box p 0.000
Jarque-Bera p 0.618
Excess Kurtosis -0.65
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.75
Market Cap 357,530,720
Forward P/E -4.09
Beta 0.43
Website https://immuneering.com

As of April 19, 2026, 1:45 a.m. EDT: Options flow displays a distinct skew toward downside protection (puts). In the near term (May expiration), put volume at the ATM strike is heavily elevated compared to call volume at the same strike, with significant out-of-the-money (OTM) put open interest concentrated at higher strikes ($7.50, $10.00). This suggests speculators are positioning for a decline or protecting against a drop, potentially due to the recent reporting of survival data for their pancreatic cancer drug which may have exceeded expectations or introduced uncertainty. Conversely, calls show bullish positioning at OTM strikes ($10.00, $7.50), but the sheer volume of Puts dominates the 1-month and 2-month expirations.


Info Dump

Attribute Value
52 Week Change 3.0072465
Address1 245 Main Street
Address2 Second Floor
All Time High 33.99
All Time Low 1.0
Ask 5.57
Ask Size 1
Audit Risk 7
Average Analyst Rating 1.2 - Strong Buy
Average Daily Volume10 Day 815,510
Average Daily Volume3 Month 967,555
Average Volume 967,555
Average Volume10Days 815,510
Beta 0.427
Bid 5.48
Bid Size 1
Board Risk 6
Book Value 3.38
City Cambridge
Compensation As Of Epoch Date 1,735,603,200
Compensation Risk 8
Country United States
Crypto Tradeable 0
Currency USD
Current Price 5.53
Current Ratio 17.496
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 5.68
Day Low 5.2775
Debt To Equity 1.75
Display Name Immuneering
Earnings Call Timestamp End 1,762,808,400
Earnings Call Timestamp Start 1,762,808,400
Earnings Timestamp 1,772,803,800
Earnings Timestamp End 1,778,011,200
Earnings Timestamp Start 1,778,011,200
Ebitda -59,022,184
Ebitda Margins 0.0
Enterprise To Ebitda -3.194
Enterprise Value 188,523,840
Eps Current Year -1.18667
Eps Forward -1.35333
Eps Trailing Twelve Months -1.27
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 5.2074
Fifty Day Average Change 0.32260036
Fifty Day Average Change Percent 0.061950374
Fifty Two Week Change Percent 300.72464
Fifty Two Week High 10.08
Fifty Two Week High Change -4.5499997
Fifty Two Week High Change Percent -0.45138887
Fifty Two Week Low 1.1
Fifty Two Week Low Change 4.4300003
Fifty Two Week Low Change Percent 4.0272727
Fifty Two Week Range 1.1 - 10.08
Financial Currency USD
First Trade Date Milliseconds 1,627,651,800,000
Float Shares 49,398,715
Forward Eps -1.35333
Forward P E -4.086217
Free Cashflow -28,047,836
Full Exchange Name NasdaqGM
Full Time Employees 53
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.17826
Held Percent Institutions 0.50802
Implied Shares Outstanding 64,652,926
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-07-30
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Long Name Immuneering Corporation
Market us_market
Market Cap 357,530,720
Market State PRE
Max Age 86,400
Message Board Id finmb_308350677
Most Recent Quarter 1,767,139,200
Net Income To Common -56,024,896
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 357,530,680
Number Of Analyst Opinions 6
Open 5.635
Operating Cashflow -45,344,596
Operating Margins 0.0
Overall Risk 7
Payout Ratio 0.0
Phone 617 500 8080
Pre Market Change -0.018900394
Pre Market Change Percent -0.34177926
Pre Market Price 5.5111
Pre Market Time 1,776,765,030
Previous Close 5.56
Price Eps Current Year -4.6600995
Price Hint 2
Price To Book 1.6360947
Profit Margins 0.0
Quick Ratio 17.157
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.2
Region US
Regular Market Change -0.03
Regular Market Change Percent -0.539564
Regular Market Day High 5.68
Regular Market Day Low 5.2775
Regular Market Day Range 5.2775 - 5.68
Regular Market Open 5.635
Regular Market Previous Close 5.56
Regular Market Price 5.53
Regular Market Time 1,776,715,201
Regular Market Volume 709,427
Return On Assets -0.2607
Return On Equity -0.43118
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 7
Shares Outstanding 64,652,926
Shares Percent Shares Out 0.1593
Shares Short 10,302,389
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 11,070,458
Short Name Immuneering Corporation
Short Percent Of Float 0.1835
Short Ratio 9.2
Source Interval 15
State MA
Symbol IMRX
Target High Price 30.0
Target Low Price 11.0
Target Mean Price 17.0
Target Median Price 14.5
Total Cash 172,831,264
Total Cash Per Share 2.673
Total Debt 3,824,425
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.27
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 5.60165
Two Hundred Day Average Change -0.07165003
Two Hundred Day Average Change Percent -0.012790878
Type Disp Equity
Volume 709,427
Website https://immuneering.com
Zip 2,142